INTRODUCTION {#s1}
============

Lung cancer is one of the most frequently diagnosed cancers and contributes to the majority of cancer-related deaths. According to the latest statistics, there were about 1.8 million new lung cancer cases and 1.5 million people who died of lung cancer in the future \[[@R1]\]. As a subtype of lung cancer, lung adenocarcinoma (LUAD) is continuously growing in the proportion of lung cancer, which is presently the top diagnosed histological type in adult men and women \[[@R2]\]. Smoking is the leading cause of lung cancer, but LUAD is the histological type showing weakness associated with smoking, which occurs mainly to non-smokers and females \[[@R3], [@R4]\]. Oncogene aberrations are now the most popular study factors that contribute to the carcinogenesis of LUAD \[[@R5], [@R6]\]. Although there are lots of contributions to individualized therapy of LUAD, patients with advanced-stage tumors have an overall survival of less than 2 years, which is mainly because they have lost the chance of surgery with a limiting selection of chemotherapy \[[@R7]\]. Besides, the molecular biomarkers that can effectively predict the outcome of LUAD patients have not been fully elucidated. Therefore it is of significant importance to figure out new LUAD special biomarkers for the diagnosis and prognosis of LUAD and to improve therapeutic effects.

In the genomics era, there emerge a lot of high throughput sequencing technologies and databases. They have contributed to the development of diagnostic and prognostic signatures of cancer. RNA-seq is a recently developed approach to deep-sequencing. It can identify unmapped genes, unrecognized non-coding RNAs and splice variants \[[@R8]\]. *Iris H. Wei* et al used RNA-seq data from international Cancer Genome Consortium and The Cancer Genome Atlas (TCGA) datasets conducting cancer-specific signatures. These signatures had high sensitivity and specificity and were able to identify metastatic cancer of unknown primary, including tumors originating from lung \[[@R9]\]. Besides, by using TCGA lung adenocarcinoma datasets, *Anlin Feng* et al found LUAD patients with high HMGB1 expression had a poor overall survival \[[@R10]\]. These indicate that these newly developed genome sequencing databases and methods can develop clinical biomarkers for LUAD. And there are some signatures which have been investigated to involve in the pathogenesis of lung cancer and have clinical associations with LUAD. Tony *et al* used a loss-of-function model to identify MALAT1 which was an active regulator of LUAD metastasis \[[@R11]\]. Ming *et al*. showed that decreased BANCER expression was associated with poor prognosis of lung cancer patients \[[@R12]\]. Gao *et al* found overexpression of serum miR-155 could be a diagnostic marker for the early detection of LUAD \[[@R13]\]. With the help of the next-generation sequencing biomarkers, we were able to detect the LUAD patients and predict the outcome of these patients in an early stage.

In this paper, in order to identify LUAD-SDGs, we analyzed large scale RNA-seq transcriptomes of 10098 tumor samples across 27 cancer types containing LUAD from TCGA. Meanwhile, dysregulated genes in LUAD were identified. Combining with the diagnostic and survival analysis, we found robust diagnostic and prognostic LUAD-SDGs. By utilizing the prognostic LUAD-SDGs, we conducted a six-gene signature that could effectively predict patients' survival.

RESULTS {#s2}
=======

Identification of specific dysregulated genes of lung adenocarcinoma (LUAD-SDGs) {#s2_1}
--------------------------------------------------------------------------------

To describe our study more clearly, we made a flow chart (Figure [1](#F1){ref-type="fig"}). We first identified the LUAD-SDGs. We found there were 112 specific expressed genes of LUAD compared with other 26 different types of cancer. The principal components analysis (PCA) demonstrated separation between LUAD and other 26 cancer types (Figure [2A](#F2){ref-type="fig"}). There were 8240 dysregulated expressed genes between LUAD tissues and normal tissues. PCA and hierarchical clustering showed clear separation and consistency in the expression profiles of the tumor and normal tissues of LUAD (Figure [2B, 2C](#F2){ref-type="fig"}). The dysregulated expressed genes of LUAD were shown with volcano plot (Figure [2D](#F2){ref-type="fig"}). We combined the results and demonstrated that there were 70 genes specifically dysregulated in LUAD (Figure [2E](#F2){ref-type="fig"}).

![Flow chart of identifying LUAD-SDGs as diagnostic or prognostic biomarkers across RNA-seq data of 27 cancer types from TCGA](oncotarget-08-87292-g001){#F1}

![Identification of LUAD-SDGs with diagnostic or prognostic power\
**(A)** PCA of the full datasets for all tumor samples from 27 cancer types. LUAD samples were marked by red dots in the PCA. **(B)** PCA of the datasets for tumor and normal samples from LUAD. The tumor samples were marked by red triangles and the normal samples were marked by blue dots. **(C)** Heatmap of differentially expressed genes between tumor and normal of LUAD. The top 100 of the most differentially expressed genes were presented. **(D)** Volcano plot of the differentially expressed gene analysis. X-axis represented log2 fold change; Y-axis meant −1 × log10 of p-value for each gene. Genes with fold change \>1 or \<-1 and p-value \< 0.05 were considered to be differentially expressed gene between tumor and normal tissues. **(E)** Venn diagram showing number of genes from differentially expressed genes (LUAD-DGs) and specifically expressed genes in LUAD (LUAD-SEGs). **(F)** Venn diagram showing the number of genes with strong diagnostic power or prognostic power among the differentially expressed genes (LUAD-DGs) and specifically expressed genes in LUAD (LUAD-SEGs). AUC-SIG(significant genes in AUC) and OS-SIG (significant genes in over survival) represented the specifically and differentially expressed genes in LUAD (LUAD-SDGs) with diagnostic values(AUC\> 95%) and prognostic values respectively(P \< 0.001).](oncotarget-08-87292-g002){#F2}

Diagnostic value of specific dysregulated genes of lung adenocarcinoma (LUAD-SDGs) {#s2_2}
----------------------------------------------------------------------------------

Next we analyzed the possible diagnostic power of LUAD-SDGs in LUAD and tried to find the LUAD-SDGs with high diagnostic value. To evaluate the prediction performance of LUAD-SDGs, we performed the receiver operative curves (ROC). LUAD-SDGs with an AUC of more than 0.95 were selected as genes that may serve as a biomarker in the diagnosis of LUAD (Figure [2F](#F2){ref-type="fig"}). As shown in Figure [3A](#F3){ref-type="fig"}, we demonstrated that there were great differences between LUAD patients and control groups. The sensitivity and specificity of MARCO, SFTPA2, SFPTA1, CHIPA2, SFTPC and RPL13AP17 were 0.9749, 0.9525, 0.9715, 0.9519, 0.9988 and 0.9673 respectively in the test group. We also showed the similar results in the validate group, whose sensitivity and specificity of MARCO, SFTPA2, SFPTA1, CHIPA2, SFTPC and RPL13AP17 were 0.9760, 0.9558, 0.9641, 0.9564, 0.9972 and 0.9803 respectively (Figure [3B](#F3){ref-type="fig"}; Table [1](#T1){ref-type="table"}). We found that SFTPC ranked top in terms of AUC in both test and validate group with average sensitivity of 100% and 97.6% specificity. These six LUAD-SDGs showed high diagnostic power in predicting LUAD, which indicated they may serve as important biomarkers in identification of LUAD. We validated the expression of the six LUAD-SDGs in the same TCGA datasets using t-test. We found that the expression of the six LUAD-SDGs was higher in LUAD than that of other tumors in 26 cancer types (log2FC \> 1, P \< 0.001). Compared with the expression of normal lung tissues, the expression of the six LUAD-SDGs was lower (log2FC \< 1, P \< 0.001) (Figure [4A, 4B](#F4){ref-type="fig"}), which confirmed that these genes were specific dysregulated genes in LUAD and were able to serve as diagnostic biomarkers for the diagnosis of LUAD.

![Receiver operating characteristic (ROC) plot for diagnostic value of six LUAD-SDGs\
**(A)** The sensitivity and specificity of MARCO, SFTPA2, SFTPA1, CHIPA2, SFTPC, and RPL13AP17 were 0.9749, 0.9525, 0.9715, 0.9519, 0.9988 and 0.9673 in the test group (n=267). **(B)** The sensitivity and specificity of MARCO, SFTPA2, SFTPA1, CHIPA2, SFTPC, and RPL13AP17 were 0.9760, 0.9558, 0.9641, 0.9564, 0.9972 and 0.9803 in the validate group (n=268).](oncotarget-08-87292-g003){#F3}

###### The detailed information of 11 LUAD-SDGs with diagnostic or prognostic values

  Ensemble ID       Gene symbol     Chromosomal position            Gene type
  ----------------- --------------- ------------------------------- ----------------
  ENSG00000019169   MARCO           Chr2: 118,942,166-118,994,660   Protein coding
  ENSG00000122852   SFTPA1          Chr10: 79,610,939-79,615,455    Protein coding
  ENSG00000168484   SFTPC           Chr8: 22,156,913-22,164,479     Protein coding
  ENSG00000185303   SFTPA2          Chr10: 79,555,852-79,560,397    Protein coding
  ENSG00000203878   CHIAP2          Chr1: 111,280,059-111,286,116   pseudogene
  ENSG00000231322   RPL13AP17       Chr7: 78,347,142-78,359,458     pseudogene
  ENSG00000260695   RP11-513N24.1   Chr16: 65,861,112-65,863,784    lincRNA
  ENSG00000248608   RP11-206P5.2    Chr4: 25,504,997-25,506,675     pseudogene
  ENSG00000168878   SFTPB           Chr2: 85,657,314-85,668,741     Protein coding
  ENSG00000112175   BMP5            Chr6: 55,753,645-55,875,564     Protein coding
  ENSG00000166961   MS4A15          Chr11: 60,756,953-60,776,732    Protein coding

![The expression (log2FPKM) of LUAD-SDGs(MARCO, SFTPA2, SFTPA1, CHIPA2, SFTPC, and RPL13AP17) with high diagnostic power in LUAD across 27 types of cancer\
**(A)** Box plot showing the expression of the six LUAD-SDGs in tumor were lower than that in normal of LUAD (P \< 0.001). **(B)** The expression (log2FPKM) distribution of the six LUAD-SDGs in 27 cancer types and the red box represented LUAD. Compared with other tumors in 26 cancer types, the expression level of the six LUAD-SDGs in LUAD was the highest (log2FC \> 1, P \< 0.001).](oncotarget-08-87292-g004){#F4}

Prognostic role of specific dysregulated genes of lung adenocarcinoma (LUAD-SDGs) {#s2_3}
---------------------------------------------------------------------------------

Then we sought to investigate the correlation between all of the 70 LUAD-SDGs and overall survival of LUAD patients. We identified that there were six LUAD-SDGs whose expression were associated with the overall survival of LUAD patients, including RP11-513N24.11, RP11-206P5.2, SFTPB, CHIAP2, BMP5 and MS4A15 (Table [1](#T1){ref-type="table"}). The Kaplan--Meier curves demonstrated that LUAD patients with higher expression of the six LUAD-SDGs had better survivals than those with low expression of the six LUAD-SDGs (log-Rank test, P \< 0.001) (Figure [5A--5F](#F5){ref-type="fig"}). In the univariate Cox regression analysis, we found that the six LUAD-SDGs were significantly associated with overall survival. Then we performed the multivariate Cox regression analysis to identify the independent prognostic role of the six LUAD-SDGs by adjusting other significant covariates including gender, stage, smoke and age. The results showed that the six LUAD-SDGs were independent prognostic factors in overall survival and were protective genes (HR \< 1) for LUAD (Figure [6A--6F](#F6){ref-type="fig"}; Table [2](#T2){ref-type="table"}). Compared with other 26 types of cancer, the expression level of the six LUAD-SDGs in LUAD was the highest (log2FC \> 1, P \< 0.001). In non-cancer tissue of LUAD, the six LUAD-SDGs had higher expression level than the cancer tissue of LUAD. All the results suggested that the six LUAD-SDGs may act as special prognostic biomarkers for LUAD patients. (Figure [7A, 7B](#F7){ref-type="fig"}).

![Kaplan--Meier survival curves analysis of the six LUAD-SDGs for overall survival of LUAD patients\
**(A-F)** The expression of six LUAD-SDGs including RP11-513N24.1, CHIAP2, RP11-206P5.2, BMP5, SFTPB and MS4A15 was positively associated with overall survival of LUAD patients (P \< 0.001).](oncotarget-08-87292-g005){#F5}

![Multivariate analysis of the six OS-related LUAD-SDGs\
**(A-F)** The expression of the six LUAD-SDGs including RP11-513N24.1, CHIAP2, RP11-206P5.2, BMP5, SFTPB and MS4A15 served as independent predict factors in LUAD.](oncotarget-08-87292-g006){#F6}

###### Univariate and multivariate Cox regression analysis of the six OS-related LUAD-SDGs and the six-gene signature

  Variables           Univariate analysis   Multivariate analysis                                           
  ------------------- --------------------- ----------------------- ---------- ---------- ----------------- ----------
  **RP11-513N24.1**   0.7601                0.6433---0.8982         0.0013     0.7733     0.6543---0.9140   0.0026
  gender              1.0508                0.7569---1.4589         0.7672     0.991154   0.7089---1.3859   0.9586
  stage               2.5857                1.8110---3.6919         1.71E-07   2.563875   1.7908---3.6707   2.72E-07
  smoke               1.1947                0.9755---1.4631         0.0854     1.167386   0.9473---1.4385   0.1464
  age                 1.0686                0.9020---1.2660         0.4431     1.087631   0.9209---1.2845   0.3224
  **RP11-206P5.2**    0.6963                0.5915---0.8198         1.38E-05   0.7008     0.5908---0.8313   4.47E-05
  gender              1.0508                0.7569---1.4589         0.7672     0.8792     0.6243---1.2382   0.4612
  stage               2.5857                1.8110---3.6919         1.71E-07   2.5147     1.7578---3.5974   4.48E-07
  smoke               1.1947                0.9755---1.4631         0.0854     1.1448     0.9291---1.4104   0.2042
  age                 1.0686                0.9020---1.2660         0.4431     1.0796     0.9122---1.2778   0.3731
  **SFTPB**           0.737                 0.6346---0.8559         0.0001     0.7627     0.6529---0.8909   0.0006
  gender              1.0508                0.7569---1.4589         0.7672     1.0336     0.7403---1.4432   0.8459
  stage               2.5857                1.8110---3.6919         1.71E-07   2.4546     1.7147---3.5138   9.29E-07
  smoke               1.1947                0.9755---1.4631         0.0854     1.1212     0.9008---1.3955   0.3058
  age                 1.0686                0.9020---1.2660         0.4431     1.1153     0.9412---1.3215   0.2077
  **CHIAP2**          0.7585                0.6339---0.9075         0.0025     0.7845     0.6548---0.9399   0.0085
  gender              1.0508                0.7569---1.4589         0.7672     1.0321     0.7392---1.4411   0.8529
  stage               2.5857                1.8110---3.6919         1.71E-07   2.4762     1.7307---3.5427   6.99E-07
  smoke               1.1947                0.9755---1.4631         0.0854     1.1744     0.9464---1.4572   0.1444
  age                 1.0686                0.9020---1.2660         0.4431     1.0878     0.9199---1.2863   0.3251
  **BMP5**            0.6858                0.5925---0.7938         4.25E-07   0.7268     0.6243---0.8461   3.9E-05
  gender              1.0508                0.7569---1.4589         0.7672     0.9943     0.7121---1.3883   0.9732
  stage               2.5857                1.8110---3.6919         1.71E-07   2.3439     1.6316---3.3672   4.1E-06
  smoke               1.1947                0.9755---1.4631         0.0854     1.0986     0.8883---1.3588   0.3857
  age                 1.0686                0.9020---1.2660         0.4431     1.0760     0.9110---1.2710   0.3882
  **MS4A15**          0.7568                0.636---0.9007          0.0017     0.7801     0.6536---0.9312   0.006
  gender              1.0508                0.7569---1.4589         0.7672     1.0126     0.7255---1.4133   0.9414
  stage               2.5857                1.8110---3.6919         1.71E-07   2.4917     1.7418---3.5646   5.81E-07
  smoke               1.1947                0.9755---1.4631         0.0854     1.1598     0.9359---1.4373   0.1755
  age                 1.0686                0.9020---1.2660         0.4431     1.0846     0.9190---1.2800   0.3367
  **Risk score**      1.5815                1.3658---1.8313         9.02E-10   1.5129     1.2988---1.7624   1.05E-07
  gender              1.0508                0.7569---1.4589         0.7672     0.9217     0.6595---1.2883   0.6333
  stage               2.5857                1.8110---3.6919         1.71E-07   2.2685     1.5805---3.2558   8.87E-06
  smoke               1.1947                0.9755---1.4631         0.0854     1.0906     0.8785---1.3539   0.4317
  age                 1.0686                0.9020---1.2660         0.4431     1.0922     0.9249---1.2898   0.2983

![The expression (log2FPKM) of six OS-related LUAD-SDGs(RP11-513N24. 1, CHIAP2, RP11-206P5.2, BMP5, SFTPB and MS4A15) across 27 types of cancer\
**(A)** Box plot showed the expression of the six LUAD-SDGs in tumor were lower than that in normal of LUAD. **(B)** The expression (log2FPKM) distribution of the six genes in 27 cancer types and the red box represented LUAD. Compared with other tumors in 26 cancer types, the expression level of the six LUAD-SDGs in LUAD was the highest (log2FC \> 1, P \< 0.001).](oncotarget-08-87292-g007){#F7}

The predictive role of a six-gene signature in LUAD {#s2_4}
---------------------------------------------------

We used the six OS-related LUAD-SDGs to construct a six-gene signature. A risk score was created based on a linear combination of the expression profiles of prognostic genes weighted by estimated regression coefficient, a risk score was created as follows: Risk score = (−0.013^\*^expression level of RP11-513N24.11) + (−0.066^\*^expression level of RP11-206P5.2) + (−0.029^\*^expression level of SFTPB) + (−0.028^\*^expression level of CHIAP2) + (−0.087^\*^expression level of BMP5) + (−0.029^\*^expression level of MS4A15). Then, patients were divided into high-risk group (n = 131) and low-risk group (n = 392) using the 75^th^ percentile risk score as the cutoff point to investigate the prognostic role of the six-gene signature in overall survival. We observed that patients in the high-risk group had lower expression of the six genes compared with low-risk group (Figure [8A](#F8){ref-type="fig"}). This was consistent with the results of multivariate Cox regression analysis of the six genes, which demonstrated that all of them were protective genes (Figure [6A--6F](#F6){ref-type="fig"}). The univariate analysis showed that the six-gene risk score was significantly related to prognosis of LUAD patients (Table [2](#T2){ref-type="table"}). The multivariate analysis indicated that the risk score statistically significantly stratified the patients for overall survival (HR =1.5129, 95%CI = 1.2988-1.7624, P \< 0.0001), independent of age, gender, smoke and pathological stage. (Figure [8B, 8C](#F8){ref-type="fig"}; Table [2](#T2){ref-type="table"}). We also evaluated the six-gene prognostic signature in patients at pathological stage I-II, pathological stage IV-III, N0 (without lymph node metastasis), M0(without distant metastasis). As a result, the stratification analysis showed that the six-gene signature could predict patients with different prognosis in different subgroups including pathological stage I-II, pathological stage IV-III, N0, M0 (Figure [8D--8G](#F8){ref-type="fig"}).

![The six-gene signature predicted overall survival of patients with LUAD\
**(A)** The six genes' expression and risk score distribution, with red indicating higher expression and blue indicating lower expression. The risk scores for all patients in LUAD were plotted in ascending order and marked as low risk (blue) or high risk (red). **(B)** Multivariate Cox regression analysis showing the risk score of the six-gene signature can serve as an independent prognostic factor in LUAD. **(C)** The Kaplan-Meier curves for all LUAD patients stratified by six-gene signature in high and low risk. **(D-G)** Kaplan-Meier curves of overall survival in the stage I-II, stage III-IV, N0 and M0 cohort stratified by six-gene signature in high and low risk.](oncotarget-08-87292-g008){#F8}

DISCUSSION {#s3}
==========

In our study, we first compared the expression of genes in 27 cancer types including LUAD between tumor and normal. As a result, all 70 LUAD-SDGs were identified. As we know, there were several known cancer-specific biomarkers that had already been translated into clinical diagnostic and prognostic signatures. For example, compared with other malignancies, alpha-fetoprotein (AFP) was specific expressed in hepatocellular carcinoma \[[@R14]\]. Besides, FUMIO *et al* showed hepatocellular carcinoma patients with normal AFP values had a better survival than those with high values, which indicated that AFP was a useful prognostic signature for hepatocellular carcinoma patients \[[@R15]\]. Welch *et al* showed prostate specific antigen (PSA) screening increased diagnosis of prostate cancer in patients younger than 50 years in the USA from 1986 to 2005 \[[@R16]\]. Inspired by these cancer-specific biomarkers, we are interested in whether the LUAD-SDGs can serve as good biomarkers for patients' diagnosis and prognosis.

In order to explore the above questions, we conducted the ROC to evaluate the diagnostic role of LUAD-SDGs. The cutoff point was selected (AUC \> 95%) and only six genes: MARCO, SFTPA1, SFTPA2, CHIPA2, SFTPC, and RPL13AP17 reached this condition. Among the six LUAD-SDGs, surfactant protein A including SFTPA1 and SFTPA2 were reported closely associated with lung cancer. It has been reported that SFTPA1 mutation was associated with familial idiopathic interstitial pneumonia and lung cancer, which shed light on the key role of SFTPA1 in the pathogenesis of several chronic respiratory diseases, especially in lung cancer \[[@R17]\]. Genetic defects in SFTPA2 were demonstrated closely related to lung cancer \[[@R18]\]. Surfactant protein A plays an important role in the maintenance of normal lung function, and the abnormal surfactant protein A may lead to the disorder of lung innate immunity and cause the occurrence of lung cancer. What\'s more, SFTPA1, SFTPA2 and SFTPC, surfactant genes which have been reported to express exclusively in type II penumocytes, have showed their unique roles in LUAD \[[@R19]\]. Meanwhile, there are some reports approving that surfactant genes such as pro--surfactant protein B (pro-SFTPB) was a promising blood biomarker for non-small-cell lung cancer. *Don D. Sin* et al showed plasma levels of pro-SFTPB were associated with early-stage lung cancer, indicating it could be used in predicting early-stage NSCLC patients. Besides, *William R. Wikoff* et al found combination of pro-SFTPB and N1, N12-diacetylspermine had a high sensitivity and specificity in diagnosing NSCLC \[[@R20], [@R21]\]. It is a great inspiration to us, as some of the six LUAD-SDGs may have the potential to become the diagnostic biomarkers for LUAD or to enhance the accuracy when combined with pathological diagnosis.

Then we explored the possible roles of LUAD-SDGs in LUAD patients' prognosis. Among the 70 LUAD-SDGs, six of them were identified significantly associated with patients' prognosis. In some studies, the expression of BMP5 demonstrated significantly lower in LUAD tissues than that in normal lung tissues, which was consistent with our result \[[@R22]\]. While there was no report about the prognostic function of BMP5, Pro--surfactant protein B (pro-SFTPB) was reported as a promising blood biomarker for non-small-cell lung cancer \[[@R20], [@R21]\]. Ayumu *et al* demonstrated that increasing concentration of plasma pro-SFTPB was associated with higher lung cancer risk, which confirmed that SFTPB might be a valuable biomarker in lung cancer risk prediction models \[[@R20], [@R23]\]. Besides, CHIAP2 was also reported associated with LUAD patients' prognosis. JING SUI et al identified that CHIAP2 was a cancer specific lncRNA and was positively correlated with OS of LUAD \[[@R24]\]. However, except for CHIAP2 and SFTPB, other four LUAD-SDGs did not have any report about the relationship between their expressions and LUAD patients' prognosis. Our study explored that the six LUAD-SDGs: BMP5, SFTPB, CHIAP2, RP11-513N24.1, RP11-206P5.2 and MS4A15 which may be positively associated with survival. In order to explore whether the six LUAD-SDGs can serve as independent prognostic factors for overall survival in LUAD, the multivariate Cox regression analysis was performed. In conclusion, the results showed that the six LUAD-SDGs were protective genes (HR \< 1) for LUAD and played independent prognostic roles in LUAD.

Finally, we used the six survival-related LUAD-SDGs to construct a six-gene signature, which proved to be a prognostic biomarker for LUAD. We also performed Cox regression analyses to evaluate whether the prognostic power of the six-gene signature was independent of other clinical variables, such as tumor stage, smoking, age and gender. We demonstrated that the prognostic power of the six-gene signature was independent after taking other clinical variables into account. Besides, in the stratified analyses, patients were classified into high-risk and low-risk groups. Similar prognostic power was tested in the early patients (stage I-II), the advanced stage(III-IV), N0 (without lymph metastasis), M0 (without distant metastasis). In general, all the results suggested that the six-gene signature owned a good independent prognostic power even when other clinical variables are taken into account. Sudhanshu Shukla *et al* first presented the RNA-seq prognostic signature consisting of four genes for LUAD \[[@R25]\]. However, in our work, we first demonstrated that LUAD-SDGs could also act as good prognostic signatures for LUAD, which could provide insights into new prognostic biomarkers exploration.

In conclusion, by analyzing the large scale RNA-seq of 10098 tumor tissues across 27 TCGA cancer types, we identified six LUAD-SDGs which showed diagnosis power. Meanwhile, other six LUAD-SDGs were significantly associated with LUAD patients' prognosis. Moreover, the six-gene signature could effectively predict patients' prognosis and function as a new independent prognostic biomarker for LUAD. But we have to admit that there are limitations in our study. Firstly, the main limitation of the study is the lack of cross-validation cohort from other databases. Validating these genes in a larger cohort of LUAD patients can make the LUAD-SDGs for diagnosis and prognosis more convincing. Secondly, the six LUAD-SDGs with diagnosis power should be validated in serums samples to own their true diagnosis value. But these limitations are certain to be solved in future investigation. \[[@R26]--[@R39]\]

MATERIALS AND METHODS {#s4}
=====================

RNA-seq data collection and processing {#s4_1}
--------------------------------------

Transcriptome data and clinical data were downloaded from The Cancer Genome Atlas (TCGA) data portal (<https://cancergenome.nih.gov/>). We chose 27 cancer types, all of which included over 100 tumor samples. We collected and analyzed data from 10098 tumor samples, which contained 535 tumor samples with related normal samples and clinical information in this study (Table [3](#T3){ref-type="table"}). The transcriptomic correlation of RNA expression was determined by RNA-seq (Fragments Per Kilobase Million \[FPKM\]) and the expression profiles were normalized by log2 transformed. To ensure the reliability of the detection, we removed genes whose FPKM values over 50% of the samples is equal to 0.

###### List of the 27 cancer types analyzed

  Cancer types                                                       Abbreviation   RNA-seq   Reference   
  ------------------------------------------------------------------ -------------- --------- ----------- ------------
  Adrenocortical Carcinoma                                           ACC            2         185         NA
  Bladder Urothelial Carcinoma                                       BLCA           19        414         \[[@R26]\]
  Breast Invasive Carcinoma                                          BRCA           113       1109        \[[@R27]\]
  Cervical Squamous Cell Carcinoma and Endocervical Adenocarcinoma   CESC           3         306         NA
  Colon Adenocarcinoma                                               COAD           41        480         \[[@R28]\]
  Esophageal Carcinoma                                               ESCA           11        162         NA
  Glioblastoma Multiforme                                            GBM            5         169         \[[@R29]\]
  Head and Neck Squamous Cell Carcinoma                              HNSC           44        502         \[[@R30]\]
  Kidney Renal Clear Cell Carcinoma                                  KIRC           72        539         \[[@R31]\]
  Kidney Renal Papillary Cell Carcinoma                              KIRP           32        289         NA
  Acute Myeloid Leukemia                                             LAML           0         151         \[[@R32]\]
  Brain Lower Grade Glioma                                           LGG            0         529         NA
  Liver Hepatocellular Carcinoma                                     LIHC           50        374         NA
  Lung Adenocarcinoma                                                LUAD           59        535         \[[@R33]\]
  Lung Squamous Cell Carcinoma                                       LUSC           49        502         \[[@R34]\]
  Ovarian Serous Cystadenocarcinoma                                  OV             0         379         \[[@R35]\]
  Pancreatic Adenocarcinoma                                          PAAD           4         178         NA
  Pheochromocytoma and Paraganglioma                                 PCPG           3         183         NA
  Prostate Adenocarcinoma                                            PRAD           52        499         \[[@R36]\]
  Rectum Adenocarcinoma                                              READ           10        167         \[[@R28]\]
  Sarcoma                                                            SARC           2         263         NA
  Skin Cutaneous Melanoma                                            SKCM           1         471         \[[@R37]\]
  Stomach Adenocarcinoma                                             STAD           32        375         \[[@R38]\]
  Testicular Germ Cell Tumors                                        TGCT           0         156         NA
  Thyroid Carcinoma                                                  THCA           58        510         NA
  Thymoma                                                            THYM           2         119         NA
  Uterine Corpus Endometrial Carcinoma                               UCEC           35        552         \[[@R39]\]
  **Total**                                                                         **699**   **10098**   

Analysis of specific dysregulated genes in LUAD {#s4_2}
-----------------------------------------------

Firstly the dysregulated genes in LUAD between tumor and normal were identified using t-test (P value\< 0.05, log2FC \> 1 or \<-1). Then the specific expressed genes of LUAD were acquired by comparing the expression of the genes between LUAD and other tumors in 26 cancer types one by one (P\< 0.05, log2FC \> 1). Specific dysregulated genes in LUAD were selected, which were specific expressed in LUAD among 27 cancer types and dysregulated expressed between tumor and normal of LUAD.

Diagnosis and survival analysis {#s4_3}
-------------------------------

All 535 LUAD patients data were randomly divided into test group (n=267) and validate group (n=268). The receiver operator characteristic (ROC) curves were used to evaluate the specificity and sensitivity of the LUAD-SDGs. The genes with high diagnostic power were selected (AUC \> 95%). Meanwhile, for overall survival analysis, Kaplan-Meier survival and log-rank test were used to compare significant differences between subgroups with univariate analysis.

Construction of a prognostic signature {#s4_4}
--------------------------------------

Univariate and multivariate Cox proportional hazards regression were used to assess the LUAD-SDGs whose expressions were significantly associated with patients' survival. Hazard ratios (HRs) from multivariable cox regression analysis were used to identify protective (HR \< 1) or risky genes (HR \> 1). Subsequently, a prognostic signature was constructed based on a linear combination of the expression profiles of prognostic genes weighted by the estimated regression coefficient \[[@R25], [@R40]--[@R42]\]. $$\textit{Risk~Score} = {\sum_{i = 1}^{N}\left( {\text{Exp}i\,*\text{ Coe}i} \right)}$$

N was the number of prognostic genes, Exp*i* was the expression of genes and Coe*i* was the coefficient value. A risk score was constructed with the regression coefficients from this model and 75^th^ percentile was chosen as the threshold.

Statistical analysis {#s4_5}
--------------------

T-test was used to compare the dysregulated genes in LUAD between tumor and normal. Besides, it was also used to analyze specific expressed genes in LUAD compared with other tumors in 26 cancer types. The receiver operating characteristic (ROC) curve was performed using R package "pROC"\[[@R43]\]. The Kaplan--Meier method with a log- rank test was used to assess patients' survival using the R packages "survival"\[[@R44]\]. The univariate and multivariable Cox proportional hazards regression were performed using the R packages "BhGLM"\[[@R45]\]. Heatmaps were generated with z-score normalization with each column using R packages "gplots"\[[@R46]\]. All analyses were performed using R software (version 3.2.2). A statistically significant difference when P value \< 0.05 was considered.
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